Pharma Mar Sau Stock Performance
| PHMMF Stock | USD 86.26 0.00 0.00% |
The company holds a Beta of -0.0639, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Pharma Mar are expected to decrease at a much lower rate. During the bear market, Pharma Mar is likely to outperform the market. At this point, Pharma Mar SAU has a negative expected return of -0.21%. Please make sure to check Pharma Mar's variance, as well as the relationship between the value at risk and day median price , to decide if Pharma Mar SAU performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Pharma Mar SAU has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's primary indicators remain nearly stable which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 96.2 M | |
| Total Cashflows From Investing Activities | 18.5 M |
Pharma |
Pharma Mar Relative Risk vs. Return Landscape
If you would invest 9,990 in Pharma Mar SAU on September 27, 2025 and sell it today you would lose (1,364) from holding Pharma Mar SAU or give up 13.65% of portfolio value over 90 days. Pharma Mar SAU is currently producing negative expected returns and takes up 1.9777% volatility of returns over 90 trading days. Put another way, 17% of traded pink sheets are less volatile than Pharma, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Pharma Mar Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharma Mar's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Pharma Mar SAU, and traders can use it to determine the average amount a Pharma Mar's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1077
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PHMMF |
Based on monthly moving average Pharma Mar is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharma Mar by adding Pharma Mar to a well-diversified portfolio.
Pharma Mar Fundamentals Growth
Pharma Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Pharma Mar, and Pharma Mar fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharma Pink Sheet performance.
| Return On Equity | 0.47 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.35 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 1.12 B | |||
| Shares Outstanding | 18.09 M | |||
| Price To Earning | 7.38 X | |||
| Price To Book | 5.60 X | |||
| Price To Sales | 5.57 X | |||
| Revenue | 229.83 M | |||
| EBITDA | 104.08 M | |||
| Cash And Equivalents | 196.7 M | |||
| Cash Per Share | 10.92 X | |||
| Total Debt | 33.39 M | |||
| Debt To Equity | 0.21 % | |||
| Book Value Per Share | 9.88 X | |||
| Cash Flow From Operations | 25.68 M | |||
| Earnings Per Share | 4.97 X | |||
| Total Asset | 368.39 M | |||
| Retained Earnings | (17 M) | |||
| Current Asset | 110 M | |||
| Current Liabilities | 78 M | |||
About Pharma Mar Performance
By analyzing Pharma Mar's fundamental ratios, stakeholders can gain valuable insights into Pharma Mar's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pharma Mar has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pharma Mar has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company was incorporated in 1986 and is based in Madrid, Spain. Pharma Mar operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 477 people.Things to note about Pharma Mar SAU performance evaluation
Checking the ongoing alerts about Pharma Mar for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Pharma Mar SAU help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharma Mar SAU generated a negative expected return over the last 90 days | |
| About 27.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Pharma Mar's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharma Mar's stock is overvalued or undervalued compared to its peers.
- Examining Pharma Mar's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharma Mar's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharma Mar's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharma Mar's pink sheet. These opinions can provide insight into Pharma Mar's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pharma Pink Sheet analysis
When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |